Project Grant R43HL182534
Award Date 9/15/25
Completion Date 8/31/26
Dollars Obligated $388K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60616, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $402,911 Project Grant to The Trustees of Columbia University in the City of New York to develop a pericardial mRNA therapy for the treatment of myocardial infarction (heart attack). The research aims to create a new anti-inflammatory drug based on previous studies of stem cell derivatives for heart repair, which will be administered via minimally invasive...
- This $1,488,899 Project Grant award was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Young Therapeutics LLC, a pharmaceutical research and development company based in Pennsylvania. The funding supports the advanced development and validation of two proprietary compounds, YT-002 and YT-004, which target specific protein kinases to preserve myocardial tissue and cardiac function following myocardial infarction. The research aims to...
- This Project Grant award of $1,290,338 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research conducted by Jaan Biotherapeutics, Inc. to develop a gene therapy treatment for heart muscle regeneration after myocardial infarction. The research aims to inhibit four specific microRNAs that regulate cardiomyocyte dedifferentiation, proliferation, and redifferentiation, with the goal of stimulating endogenous heart muscle regeneration and...
- The National Heart Lung and Blood Institute (NHLBI) awarded a $129,021 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University to develop injectable liposome nanoparticle crosslinked (LINC) hydrogels for sustained delivery of protein therapeutics to treat myocardial infarction (MI). The research aims to synthesize a library of HA-LINC hydrogels, optimize liposome stabilization, and evaluate the gels' viscoelastic properties,...
- The federal Project Grant award, titled "Focal Myocardial Delivery of Small Molecule Nitroalkenes Using Ultrasound Targeted Microbubble Cavitation to Improve Ventricular Recovery Following Myocardial Infarction," was awarded by the National Heart Lung and Blood Institute under CFDA 93.837, the Cardiovascular Diseases Research program. The $720,676 award, with a start date of March 4, 2025 and an ultimate completion date of December 31, 2028, aims to develop a novel therapeutic strategy...
- This Project Grant award of $2,095,748.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports pre-clinical studies to demonstrate the efficacy and dosing of the therapeutic CAM-6019, which is based on the mechanisms of neonatal cardiac regeneration. The objective is to develop a regenerative therapy that can protect cardiac tissue, reduce adverse remodeling, and enable cardiac regeneration for patients with heart failure. The award...
- This $298,368 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a novel device for treating mitral valve regurgitation. The project aims to optimize the device design and procedure through bench testing, followed by acute in vivo studies to demonstrate the feasibility of the approach. The funding recipient, Link Medical LLC, has invented a catheter-based technology intended to restore proper mitral...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $464,229 to Limax Biosciences Inc. to advance the development of their HEMOMAX biodegradable hydrogel sealant for use in vascular surgery. The key objectives are to: (1) conduct comprehensive bench performance testing, including sterilization validation and endotoxin assessment, and (2) evaluate the safety and efficacy of HEMOMAX in a...
- This Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), funds the development of Heartpoint Global's IntelliSent - a minimally invasive, adjustable pulmonary flow restrictor system for pediatric and congenital heart disease patients. The $1,771,084 award supports efforts to (1) downsize the IntelliSent device to be suitable for patients from birth, including preclinical testing, (2) complete...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $275,739 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to WR Biotech, LLC, a small disadvantaged business. The grant supports research on a novel technique called Improved Synchronization Modulation Electric Field (I-SMEF) to protect donor hearts and improve transplanted heart graft function during cold storage prior to heart transplantation in mice. The I-SMEF technique aims to maintain...